A real-world pharmacovigilance study of cardiac adverse events induced by sugammadex in the FDA adverse event reporting system

Background Sugammadex is a novel agent that reverses neuromuscular blockade during general anesthesia. Recent case reports have raised concerns regarding potential cardiac adverse events (CAEs). However, no large-scale real-world studies have yet evaluated the potential link between sugammadex and CAEs.